醫藥股普遍跑輸大市 科倫博泰、再鼎、榮昌及來凱醫藥挫逾8%-9%
內地近期爆出包括流感、肺炎支原體及呼吸道合胞病毒等的「多病原疫情」。然而,A股的流感、生物疫苗及醫藥生物板塊卻跟隨大市下跌。本港醫藥股沽壓普遍超大市,尤其是科倫博泰生物-B(06990.HK)、再鼎醫藥(09688.HK)、榮昌生物(09995.HK)及來凱醫藥-B(02105.HK)沽壓最大,股價挫逾8%-9%,現報87.3元、19.12元、36.4元及13.74元。
艾美疫苗(06660.HK)挫逾5%曾低見7.64元屢創上市新低。泰格醫藥(03347.HK)低見33.5元再創上市新低,現報34.25元,續跌3.1%。
上海醫藥(02607.HK)、君實生物(01877.HK)、康諾亞-B(02162.HK)、百濟神州(06160.HK)及康希諾(06185.HK)跌逾2%-3.5%,後兩者跑輸,股價曾分別低見101.3元及22.35元。
藍籌石藥(01093.HK)、藥明生物(02269.HK)、翰森(03692.HK)及中生(01177.HK)跌逾2%-4%,後者沽壓最大報3.23元,藥明生物曾低見28.1元創逾四年低。
然而,已完成向巴西申報季節性流感疫苗上市的三葉草生物-B(02197.HK)逆市回升16%報0.66元,股價重越10天線(0.65元)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.